In vitro antibacterial activity of a new quinolone drug for oral use, balofloxacin, and its clinical effects on respiratory infectious diseases

K. Takagi, T. Arai, K. Ogawa, K. Matsumoto, Y. Noda, H. Gonda, M. Tano, M. Kondo, M. Hara, J. Shindoh, M. Horiba, Y. Watanabe, H. Tanaka

研究成果: Article

抄録

The antibacterial activity of a new quinolone drug for oral use, balofloxacin (BLFX), against fresh clinical isolates (between November 1992 and March 1993) was investigated. Sensitivities of Staphylococcus aureus, Staphylococcus epidermidis and Streptococcus pneumoniae to BLFX were distributed in the 0.1 ~1.56 μg/ml range, and the activity was more potent than that of ofloxacin (OFLX), by 2~4 times, and those of norfloxacin (NFLX) and enoxacin (ENX), by 4~8 times. BLFX exhibited activity against Haemophilus influenzae which was 4 times stronger than those of OFLX and ENX. Although the activity of BLFX against Klebsiella pneumoniae was inferior to those of OFLX and ENX, by 2~4 times, it was equivalent to that of NFLX. The clinical effects of BLFX on respiratory infectious diseases were investigated in 14 patients. The clinical efficacy was excellent in 4 and effective in 7, all of whom showed improvement in infectious symptoms. In 5 patients with pneumonia, including one with mycoplasma pneumonia and 2 with acute bronchitis particularly, the symptoms were markedly improved. Ten pyogenic bacterial strains were isolated from 10 patients, and all were eradicated in the 7 patients in whom bacteriological evaluation was possible. Mild loss of apetite and elevated S-GPT and BUN were observed, but no specific problematic side effects appeared. This new quinolone drug, for oral use, was considered to be a safe and useful in chemotherapy for respiratory infectious diseases.

元の言語English
ページ(範囲)236-241
ページ数6
ジャーナルJapanese Journal of Chemotherapy
43
発行部数SUPPL. 5
出版物ステータスPublished - 01-12-1995

Fingerprint

Quinolones
Communicable Diseases
Enoxacin
Ofloxacin
Norfloxacin
Pharmaceutical Preparations
Mycoplasma Pneumonia
Staphylococcus epidermidis
Bronchitis
Blood Urea Nitrogen
Haemophilus influenzae
Klebsiella pneumoniae
Streptococcus pneumoniae
Staphylococcus aureus
Pneumonia
In Vitro Techniques
balofloxacin
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

これを引用

Takagi, K., Arai, T., Ogawa, K., Matsumoto, K., Noda, Y., Gonda, H., ... Tanaka, H. (1995). In vitro antibacterial activity of a new quinolone drug for oral use, balofloxacin, and its clinical effects on respiratory infectious diseases. Japanese Journal of Chemotherapy, 43(SUPPL. 5), 236-241.
Takagi, K. ; Arai, T. ; Ogawa, K. ; Matsumoto, K. ; Noda, Y. ; Gonda, H. ; Tano, M. ; Kondo, M. ; Hara, M. ; Shindoh, J. ; Horiba, M. ; Watanabe, Y. ; Tanaka, H. / In vitro antibacterial activity of a new quinolone drug for oral use, balofloxacin, and its clinical effects on respiratory infectious diseases. :: Japanese Journal of Chemotherapy. 1995 ; 巻 43, 番号 SUPPL. 5. pp. 236-241.
@article{7a084bb9b12644299d545380ff9c8297,
title = "In vitro antibacterial activity of a new quinolone drug for oral use, balofloxacin, and its clinical effects on respiratory infectious diseases",
abstract = "The antibacterial activity of a new quinolone drug for oral use, balofloxacin (BLFX), against fresh clinical isolates (between November 1992 and March 1993) was investigated. Sensitivities of Staphylococcus aureus, Staphylococcus epidermidis and Streptococcus pneumoniae to BLFX were distributed in the 0.1 ~1.56 μg/ml range, and the activity was more potent than that of ofloxacin (OFLX), by 2~4 times, and those of norfloxacin (NFLX) and enoxacin (ENX), by 4~8 times. BLFX exhibited activity against Haemophilus influenzae which was 4 times stronger than those of OFLX and ENX. Although the activity of BLFX against Klebsiella pneumoniae was inferior to those of OFLX and ENX, by 2~4 times, it was equivalent to that of NFLX. The clinical effects of BLFX on respiratory infectious diseases were investigated in 14 patients. The clinical efficacy was excellent in 4 and effective in 7, all of whom showed improvement in infectious symptoms. In 5 patients with pneumonia, including one with mycoplasma pneumonia and 2 with acute bronchitis particularly, the symptoms were markedly improved. Ten pyogenic bacterial strains were isolated from 10 patients, and all were eradicated in the 7 patients in whom bacteriological evaluation was possible. Mild loss of apetite and elevated S-GPT and BUN were observed, but no specific problematic side effects appeared. This new quinolone drug, for oral use, was considered to be a safe and useful in chemotherapy for respiratory infectious diseases.",
author = "K. Takagi and T. Arai and K. Ogawa and K. Matsumoto and Y. Noda and H. Gonda and M. Tano and M. Kondo and M. Hara and J. Shindoh and M. Horiba and Y. Watanabe and H. Tanaka",
year = "1995",
month = "12",
day = "1",
language = "English",
volume = "43",
pages = "236--241",
journal = "Japanese Journal of Chemotherapy",
issn = "1340-7007",
publisher = "Japan Society of Chemotherapy",
number = "SUPPL. 5",

}

Takagi, K, Arai, T, Ogawa, K, Matsumoto, K, Noda, Y, Gonda, H, Tano, M, Kondo, M, Hara, M, Shindoh, J, Horiba, M, Watanabe, Y & Tanaka, H 1995, 'In vitro antibacterial activity of a new quinolone drug for oral use, balofloxacin, and its clinical effects on respiratory infectious diseases', Japanese Journal of Chemotherapy, 巻. 43, 番号 SUPPL. 5, pp. 236-241.

In vitro antibacterial activity of a new quinolone drug for oral use, balofloxacin, and its clinical effects on respiratory infectious diseases. / Takagi, K.; Arai, T.; Ogawa, K.; Matsumoto, K.; Noda, Y.; Gonda, H.; Tano, M.; Kondo, M.; Hara, M.; Shindoh, J.; Horiba, M.; Watanabe, Y.; Tanaka, H.

:: Japanese Journal of Chemotherapy, 巻 43, 番号 SUPPL. 5, 01.12.1995, p. 236-241.

研究成果: Article

TY - JOUR

T1 - In vitro antibacterial activity of a new quinolone drug for oral use, balofloxacin, and its clinical effects on respiratory infectious diseases

AU - Takagi, K.

AU - Arai, T.

AU - Ogawa, K.

AU - Matsumoto, K.

AU - Noda, Y.

AU - Gonda, H.

AU - Tano, M.

AU - Kondo, M.

AU - Hara, M.

AU - Shindoh, J.

AU - Horiba, M.

AU - Watanabe, Y.

AU - Tanaka, H.

PY - 1995/12/1

Y1 - 1995/12/1

N2 - The antibacterial activity of a new quinolone drug for oral use, balofloxacin (BLFX), against fresh clinical isolates (between November 1992 and March 1993) was investigated. Sensitivities of Staphylococcus aureus, Staphylococcus epidermidis and Streptococcus pneumoniae to BLFX were distributed in the 0.1 ~1.56 μg/ml range, and the activity was more potent than that of ofloxacin (OFLX), by 2~4 times, and those of norfloxacin (NFLX) and enoxacin (ENX), by 4~8 times. BLFX exhibited activity against Haemophilus influenzae which was 4 times stronger than those of OFLX and ENX. Although the activity of BLFX against Klebsiella pneumoniae was inferior to those of OFLX and ENX, by 2~4 times, it was equivalent to that of NFLX. The clinical effects of BLFX on respiratory infectious diseases were investigated in 14 patients. The clinical efficacy was excellent in 4 and effective in 7, all of whom showed improvement in infectious symptoms. In 5 patients with pneumonia, including one with mycoplasma pneumonia and 2 with acute bronchitis particularly, the symptoms were markedly improved. Ten pyogenic bacterial strains were isolated from 10 patients, and all were eradicated in the 7 patients in whom bacteriological evaluation was possible. Mild loss of apetite and elevated S-GPT and BUN were observed, but no specific problematic side effects appeared. This new quinolone drug, for oral use, was considered to be a safe and useful in chemotherapy for respiratory infectious diseases.

AB - The antibacterial activity of a new quinolone drug for oral use, balofloxacin (BLFX), against fresh clinical isolates (between November 1992 and March 1993) was investigated. Sensitivities of Staphylococcus aureus, Staphylococcus epidermidis and Streptococcus pneumoniae to BLFX were distributed in the 0.1 ~1.56 μg/ml range, and the activity was more potent than that of ofloxacin (OFLX), by 2~4 times, and those of norfloxacin (NFLX) and enoxacin (ENX), by 4~8 times. BLFX exhibited activity against Haemophilus influenzae which was 4 times stronger than those of OFLX and ENX. Although the activity of BLFX against Klebsiella pneumoniae was inferior to those of OFLX and ENX, by 2~4 times, it was equivalent to that of NFLX. The clinical effects of BLFX on respiratory infectious diseases were investigated in 14 patients. The clinical efficacy was excellent in 4 and effective in 7, all of whom showed improvement in infectious symptoms. In 5 patients with pneumonia, including one with mycoplasma pneumonia and 2 with acute bronchitis particularly, the symptoms were markedly improved. Ten pyogenic bacterial strains were isolated from 10 patients, and all were eradicated in the 7 patients in whom bacteriological evaluation was possible. Mild loss of apetite and elevated S-GPT and BUN were observed, but no specific problematic side effects appeared. This new quinolone drug, for oral use, was considered to be a safe and useful in chemotherapy for respiratory infectious diseases.

UR - http://www.scopus.com/inward/record.url?scp=0029586395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029586395&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0029586395

VL - 43

SP - 236

EP - 241

JO - Japanese Journal of Chemotherapy

JF - Japanese Journal of Chemotherapy

SN - 1340-7007

IS - SUPPL. 5

ER -